<DOC>
	<DOCNO>NCT01493557</DOCNO>
	<brief_summary>This prospective open label study aim enroll approximately 1200 patient non-valvular atrial fibrillation ( NVAF ) previously treat Pradaxa® free gastrointestinal symptom ( GIS ) least 2 week prior enrolment . Approximately 125 site North America recruit . Patients report GIS 3 month treatment period randomize one two management strategy , data document intensity duration GIS collect .</brief_summary>
	<brief_title>A Prospective , Open Label Study Evaluating Two Management Strategies Gastrointestinal Symptoms Patients Newly Treatment With Pradaxa Prevention Stroke Systemic Embolism With Non-valvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Inclusion criterion : 1 . Documented nonvalvular atrial fibrillation ( NVAF ) Pradaxa® ( dabigatran etexilate ) indicate per current local label , receive treatment Pradaxa® ( dabigatran etexilate ) , start Pradaxa® ( dabigatran etexilate ) 7 day prior potential enrolment study . NVAF may document 12lead electrocardiogram , rhythm strip , pacemaker/ implantable cardioverter defibrillator ( ICD ) electrograms Holter monitor 2 . Male female patient , age great equal 18 year entry 3 . Written , inform consent Exclusion criterion : 1 . History within 2 week follow gastrointestinal ( GI ) disorder : heartburn , indigestion , gastritis , upper abdominal pain discomfort , gastroesophageal reflux require use proton pump inhibitor , histamine2 receptor blocker antacid . Patients nausea and/or vomit within 2 week exclude symptom clearly associate selflimited acute febrile illness . Shortterm use PPIs , prophylaxis , hospital set prevention stress ulcer acceptable . Calcium carbonate supplement calcium replacement exclusionary ( long product use calcium supplementation/replacement use treat relieve GIS . ) 2 . GI bleed within one year history symptomatic endoscopically document gastroduodenal ulcer diverticulitis , unless cause permanently eliminate medical therapy surgery ( e.g. , patient peptic ulcer disease endoscopically proven cure therapy lower GI bleed due diverticulosis cure segmental colectomy exclude . ) 3 . Contraindication pantoprazole proton pump inhibitor , e.g . omeprazole , lansoprazole , rabeprazole , atnoprazole , esomeprazole 4 . Contraindication Pradaxa® ( dabigatran etexilate ) know hypersensitivity Pradaxa® ( dabigatran etexilate ) excipients 5 . Hemorrhagic disorder , bleed diathesis active pathological bleeding 6 . Need anticoagulant treatment disorder atrial fibrillation 7 . Current treatment rifampin 8 . Creatinine clearance &lt; 15ml/min ( Canada , &lt; 30ml/min ) , patient renal replacement therapy ( dialysis ) 9 . Premenopausal woman ( last menstruation less equal 1 year prior informed consent ) : nursing pregnant , child bear potential practicing acceptable method birth control , plan continue use method throughout study . Acceptable method birth control include abstinence , tubal ligation , transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral implantable injectable contraceptive , double barrier method vasectomize partner . 10 . Patients receive investigational drug past 30 day participate another drug study 11 . Patients consider unreliable investigator concern requirement followup study 12 . Any condition investigator believe would allow safe participation study 13 . Contraindication patient mechanical heart valve . The use Pradaxa setting form valvular heart disease , include presence bioprosthetic valve , recommend .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>